Use of Interleukin-11 to Prevent Immune-Mediated Cytotoxicity

Abstract

The use of interleukin-11 to prevent, to ameliorate, and to treat an immune-mediated disease in a mammal in need of such treatment is disclosed.

1 . A method of preventing an immune-mediated disorder which comprises administering to a mammal, prior to tissue transplantation, a therapeutically effective amount of interleukin-11. 
   
   
       2 . The method of  claim 1 , wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 μg/kg body weight. 
   
   
       3 . A method of ameliorating an immune-mediated disorder which comprises administering to a mammal, at the time of tissue transplantation, a therapeutically effective amount of interleukin-11. 
   
   
       4 . The method of  claim 3 , wherein the therapeutically effective amount of interleukin-11 comprises 1 ng to 100 μg/kg body weight. 
   
   
       5 . The method of  claim 4 , wherein the interleukin-11 is administered for three days beginning on the day of the tissue transplant. 
   
   
       6 . A method of treating an immune-mediated disorder which comprises administering to a mammal experiencing said immune-mediated disorder a therapeutically effective amount of interleukin-11. 
   
   
       7 . The method of  claim 6 , wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 μg/kg body weight. 
   
   
       8 . The method of  claim 7 , wherein the interleukin-11 is administered daily until improvement of the immune-mediated disorder is observed. 
   
   
       9 . The method of  claim 7 , wherein the interleukin-11 is administered daily until remission of the immune-mediated disorder is observed.